ISG20 promotes local tumor immunity and contributes to poor survival in human glioma

Gao, Mengqi; Lin, Yi; Liu, Xing; Li, Yiming; Zhang, Chuanbao; Wang, Zheng; Wang, Zhiliang; Wang, Yulin; Guo, Zongze

To further determine the prognostic value of ISG20, we carried out Cox regression analyses in the CGGA and TCGA databases, respectively. In the CGGA database, ISG20 emerged as an independent prognostic factor of patient survival (hazard ratio = 1.058, 95%CI = 1.024-1.093, p = 0.001), independent of age, tumor grade, chemo-and radiation Figure 1 . Numbers of differentially expressed genes according to IDH status in four groups of samples. Genes were analyzed in four cohorts: low-grade gliomas in CGGA cohort (CGGA LGGs), glioblastomas in CGGA cohort (CGGA GBMs), low-grade gliomas in TCGA cohort (TCGA LGGs), and glioblastomas in TCGA cohort (TCGA GBMs). Genes that were both significant in Student's t-test (p < 0.05) and SAM (FDR < 0.01) were counted. Each digit represents the number of significantly upregulated genes in the corresponding group. The overlapped genes across four groups were selected for further survival analysis. therapy, IDH mutation, 1p19q-co-deletion status, and MGMT promoter methylation (Table 1) . Analysis in TCGA database showed the same result (hazard ratio = 1.250, 95%CI = 1.070-1.460, p = 0.005, Table 1 ). The samples were further stratified based on IDH status and tumor grades. As shown in Figure 3 and Fig. S2 , high ISG20 expression (i.e. higher than the median ISG20 level) was associated with shorter patient survival across all subgroups, except for grade II glioma (Figure 3, Fig. S2 ).